MEK/ERK Dependent Activation of STAT1 Mediates Dasatinib-Induced Differentiation of Acute Myeloid Leukemia

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Fang, Yanfen ^a,b   Zhong, Like ^a   Lin, Meihua ^a   Zhou, Xinglu ^a   Jing, Hui ^a   Ying, Meidan ^a   Luo, Peihua ^a   Yang, Bo ^a   He, Qiaojun ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; CD11B ANTIGEN; DASATINIB; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; SERINE; STAT1 PROTEIN; TYROSINE; U 0216; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL CYCLE PROGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL VIABILITY; CELLULAR PARAMETERS; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; HUMAN; HUMAN CELL; LEUKEMIA CELL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; TRANSCRIPTION INITIATION;

ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL LINE, TUMOR; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GENE KNOCKDOWN TECHNIQUES; HUMANS; LEUKEMIA, MYELOID, ACUTE; MAP KINASE KINASE KINASES; MAP KINASE SIGNALING SYSTEM; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; STAT1 TRANSCRIPTION FACTOR; THIAZOLES;

EID: 84879382833     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0066915     Document Type: Article

References (42)

1. Wouters BJ, Lowenberg B, Delwel R, (2009) A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. Blood 113: 291-298.
2. Burnett A, Wetzler M, Lowenberg B, (2011) Therapeutic advances in acute myeloid leukemia. J Clin Oncol 29: 487-494.
3. Nowak D, Stewart D, Koeffler HP, (2009) Differentiation therapy of leukemia: 3 decades of development. Blood 113: 3655-3665.
4. Petrie K, Zelent A, Waxman S, (2009) Differentiation therapy of acute myeloid leukemia: past, present and future. Curr Opin Hematol 16: 84-91.
5. Wang ZY, Chen Z, (2008) Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 111: 2505-2515.
6. Gianni M, Kalac Y, Ponzanelli I, Rambaldi A, Terao M, et al. (2001) Tyrosine kinase inhibitor STI571 potentiates the pharmacologic activity of retinoic acid in acute promyelocytic leukemia cells: effects on the degradation of RARalpha and PML-RARalpha. Blood 97: 3234-3243.
7. Miranda MB, Duan R, Thomas SM, Grandis JR, Redner RL, et al. (2008) Gefitinib potentiates myeloid cell differentiation by ATRA. Leukemia 22: 1624-1627.
8. Stegmaier K, Corsello SM, Ross KN, Wong JS, Deangelo DJ, et al. (2005) Gefitinib induces myeloid differentiation of acute myeloid leukemia. Blood 106: 2841-2848.
9. Sullivan C, Peng C, Chen Y, Li D, Li S, (2010) Targeted therapy of chronic myeloid leukemia. Biochem Pharmacol 80: 584-591.
10. Rosenzweig SA, (2012) Acquired resistance to drugs targeting receptor tyrosine kinases. Biochem Pharmacol 83: 1041-1048.
11. Shami PJ, Deininger M, (2012) Evolving treatment strategies for patients newly diagnosed with chronic myeloid leukemia: the role of second-generation BCR-ABL inhibitors as first-line therapy. Leukemia 26: 214-224.
12. Borriello A, Caldarelli I, Basile MA, Bencivenga D, Tramontano A, et al. (2011) The tyrosine kinase inhibitor dasatinib induces a marked adipogenic differentiation of human multipotent mesenchymal stromal cells. PLoS One 6: e28555.
13. Guerrouahen BS, Futami M, Vaklavas C, Kanerva J, Whichard ZL, et al. (2010) Dasatinib inhibits the growth of molecularly heterogeneous myeloid leukemias. Clin Cancer Res 16: 1149-1158.
14. Kolb EA, Gorlick R, Houghton PJ, Morton CL, Lock RB, et al. (2008) Initial testing of dasatinib by the pediatric preclinical testing program. Pediatr Blood Cancer 50: 1198-1206.
15. Kropf PL, Wang L, Zang Y, Redner RL, Johnson DE, (2010) Dasatinib promotes ATRA-induced differentiation of AML cells. Leukemia 24: 663-665.
16. Congleton J, Macdonald R, Yen A, (2012) Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells. Leukemia 26: 1180-1188.
17. Lainey E, Thepot S, Bouteloup C, Sebert M, Ades L, et al. (2011) Tyrosine kinase inhibitors for the treatment of acute myeloid leukemia: delineation of anti-leukemic mechanisms of action. Biochem Pharmacol 82: 1457-1466.
18. Chevalier N, Solari ML, Becker H, Pantic M, Gartner F, et al. (2010) Robust in vivo differentiation of t(8;21)-positive acute myeloid leukemia blasts to neutrophilic granulocytes induced by treatment with dasatinib. Leukemia 24: 1779-1781.
19. Fang Y, Zhou X, Lin M, Ying M, Luo P, et al. (2011) Inhibition of all-trans-retinoic acid-induced proteasome activation potentiates the differentiating effect of retinoid in acute myeloid leukemia cells. Mol Carcinog 50: 24-35.
20. Luo P, Lin M, Li L, Yang B, He Q, (2011) The proteasome inhibitor bortezomib enhances ATRA-induced differentiation of neuroblastoma cells via the JNK mitogen-activated protein kinase pathway. PLoS One 6: e27298.
21. Gu ZM, Liu CX, Wu SF, Zhao M, Xu HZ, et al. (2011) PU.1 directly regulates retinoic acid-induced expression of RIG-G in leukemia cells. FEBS Lett 585: 375-380.
22. Rivieccio MA, John GR, Song X, Suh HS, Zhao Y, et al. (2005) The cytokine IL-1beta activates IFN response factor 3 in human fetal astrocytes in culture. J Immunol 174: 3719-3726.
23. Fang Y, Zhou X, Lin M, Jing H, Zhong L, et al. (2010) The ubiquitin-proteasome pathway plays essential roles in ATRA-induced leukemia cells G0/G1 phase arrest and transition into granulocytic differentiation. Cancer Biol Ther 10: 1157-1167.
24. Fey A, Eichler S, Flavier S, Christen R, Hofle MG, et al. (2004) Establishment of a real-time PCR-based approach for accurate quantification of bacterial RNA targets in water, using Salmonella as a model organism. Appl Environ Microbiol 70: 3618-3623.
25. Xiao S, Li D, Zhu HQ, Song MG, Pan XR, et al. (2006) RIG-G as a key mediator of the antiproliferative activity of interferon-related pathways through enhancing p21 and p27 proteins. Proc Natl Acad Sci U S A 103: 16448-16453.
26. Weber S, Maass F, Schuemann M, Krause E, Suske G, et al. (2009) PRMT1-mediated arginine methylation of PIAS1 regulates STAT1 signaling. Genes Dev 23: 118-132.
27. Dimberg A, Nilsson K, Oberg F, (2000) Phosphorylation-deficient Stat1 inhibits retinoic acid-induced differentiation and cell cycle arrest in U-937 monoblasts. Blood 96: 2870-2878.
28. Zhang Y, Cho YY, Petersen BL, Zhu F, Dong Z, (2004) Evidence of STAT1 phosphorylation modulated by MAPKs, MEK1 and MSK1. Carcinogenesis 25: 1165-1175.
29. Li SW, Lai CC, Ping JF, Tsai FJ, Wan L, et al. (2011) Severe acute respiratory syndrome coronavirus papain-like protease suppressed alpha interferon-induced responses through downregulation of extracellular signal-regulated kinase 1-mediated signalling pathways. J Gen Virol 92: 1127-1140.
30. Nguyen H, Ramana CV, Bayes J, Stark GR, (2001) Roles of phosphatidylinositol 3-kinase in interferon-gamma-dependent phosphorylation of STAT1 on serine 727 and activation of gene expression. J Biol Chem 276: 33361-33368.
31. Benekli M, Baumann H, Wetzler M, (2009) Targeting signal transducer and activator of transcription signaling pathway in leukemias. J Clin Oncol 27: 4422-4432.
32. Gianni M, Terao M, Fortino I, LiCalzi M, Viggiano V, et al. (1997) Stat1 is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood 89: 1001-1012.
33. Schindler C, Levy DE, Decker T, (2007) JAK-STAT signaling: from interferons to cytokines. J Biol Chem 282: 20059-20063.
34. Qing Y, Stark GR, (2004) Alternative activation of STAT1 and STAT3 in response to interferon-gamma. J Biol Chem 279: 41679-41685.
35. Schuringa JJ, Wierenga AT, Kruijer W, Vellenga E, (2000) Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6. Blood 95: 3765-3770.
36. Redell MS, Ruiz MJ, Alonzo TA, Gerbing RB, Tweardy DJ, (2011) Stat3 signaling in acute myeloid leukemia: ligand-dependent and-independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood 117: 5701-5709.
37. Panopoulos AD, Zhang L, Snow JW, Jones DM, Smith AM, et al. (2006) STAT3 governs distinct pathways in emergency granulopoiesis and mature neutrophils. Blood 108: 3682-3690.
38. Miranda MB, Johnson DE, (2007) Signal transduction pathways that contribute to myeloid differentiation. Leukemia 21: 1363-1377.
39. Hazan-Halevy I, Harris D, Liu Z, Liu J, Li P, et al. (2010) STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood 115: 2852-2863.
40. Vera J, Rateitschak K, Lange F, Kossow C, Wolkenhauer O, et al. (2011) Systems biology of JAK-STAT signalling in human malignancies. Prog Biophys Mol Biol 106: 426-434.
41. Johnson DE, (2008) Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis. Adv Enzyme Regul 48: 98-112.
42. Packer LM, Rana S, Hayward R, O'Hare T, Eide CA, et al. (2011) Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia. Cancer Cell 20: 715-727.